[{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"1079f78e-9ce0-445a-837c-c2dc7bc96947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275426","created_at":"2022-03-11T15:53:40.436Z","updated_at":"2024-07-02T16:35:13.985Z","phase":"Phase 2","brief_title":"A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor","source_id_and_acronym":"NCT05275426","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4","pipe":" | ","alterations":" EWSR1-WT1 fusion","tags":["WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EWSR1-WT1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ESP-01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2024-03-19"},{"id":"c593289f-379a-464c-a6a5-1f0db0f60d24","acronym":"TAPG","url":"https://clinicaltrials.gov/study/NCT03912883","created_at":"2021-01-18T19:15:24.719Z","updated_at":"2024-07-02T16:35:42.041Z","phase":"","brief_title":"Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting","source_id_and_acronym":"NCT03912883 - TAPG","lead_sponsor":"Queen Mary University of London","biomarkers":" ETV1","pipe":"","alterations":" ","tags":["ETV1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3350","initiation":"Initiation: 10/12/1999","start_date":" 10/12/1999","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2023-07-25"}]